Clorox’s (NYSE:CLX) Q3 CY2026 sales top estimates
Clorox (NYSE:CLX) reported Q3 CY2026 revenue of $1.91B, up 33.3% YoY and 1.5% above estimates. Adjusted EPS of $1.55 beat estimates by 44.6%. Management reiterated full-year EPS guidance of $5.85 at the midpoint. Organic revenue rose 18% YoY. CEO Linda Rendle cited strong execution and timing benefits but noted higher inflationary pressures. Shares rose 2.1% post-results.
How this was made
The 30-second read
Why it matters
Earnings beat and reaffirmed guidance support a short‑term bullish stance, but cost inflation remains a risk.
Market read
The earnings surprise and guidance reaffirmation provide a clear catalyst for CLX traders, with modest upside potential.
What to watch
Integration of GOJO Purell ProCare and inflationary cost pressures could affect future performance.
Background
Clorox is a large consumer‑products company with a market cap of ~$10.6B, reporting its Q3 CY2026 results (fiscal Q1 2027).
Ticker impact
Clorox reported Q3 CY2026 revenue of $1.91B beating estimates and EPS of $1.55 beating consensus, with shares up 2.1% after the release.
likely modest upward pressure as the market prices in the earnings beat and guidance reaffirmation
Revenue and EPS both exceeded expectations; management reiterated full‑year EPS guidance, and the stock already rose 2% on the news.
Market effects
Strong beat may lift other consumer‑staples peers as investors reassess sector growth outlook.
U.S. consumer‑staples market may see modest buying pressure.
Limited to U.S. equities; no broader macro impact.
Counterpoint
The beat may be temporary; higher input costs could pressure margins in upcoming quarters.
Key entities
- ExecutiveLinda Rendle
Chair and CEO of Clorox, provided commentary on results.
